SONNEST

Sonnest - the first electrically sensitive imaging agent for assessing monitoring the perfusion, structure, function of the heart... The inspiration for Electrast™ began in 2015 through a collaboration between Dr. Wrenn, the company's Chief Scientific Officer and professor of Chemical Engineering at Drexel University, and Dr. Brett Angel, an electrophysiologist at Drexel. The team began experimenting to create a voltage-activated ultrasound contrast agent and secured a grant from the Drexel Coulter Foundation to support the initial development work. In 2019, the Drexel inventors partnered with a team of successful healthcare executives and entrepreneurs to form Sonnest, and to continue product development of and commercialization of Electrast™... Sonnest's team combines extensive startup experience, business acumen and clinical expertise in the cardiology and electrophysiology.

Primary location: Baltimore United States